Jul 2, 2025 06:36AM
Jul 1, 2025 12:03PM
Jul 1, 2025 07:03AM
Jul 1, 2025 07:00AM
May 21, 2025 04:54PM
May 9, 2025 05:16AM
May 7, 2025 07:00AM Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
Apr 29, 2025 06:32AM
Apr 1, 2025 07:01AM
Apr 1, 2025 07:00AM
May 31, 2024 10:23AM
Jul 31, 2023 07:00AM
Jul 17, 2023 06:53AM
May 4, 2023 04:05PM Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
Feb 21, 2023 04:13PM
Feb 21, 2023 04:13PM
Jan 5, 2023 07:05AM
Jan 5, 2023 07:00AM
Jan 5, 2023 07:00AM
Dec 16, 2022 07:02AM
Dec 16, 2022 07:00AM Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy
Dec 16, 2022 07:00AM
Nov 18, 2022 12:25PM
Nov 18, 2022 09:04AM
Nov 18, 2022 07:01AM
Nov 18, 2022 07:00AM
Nov 18, 2022 07:00AM
Nov 7, 2022 04:05PM Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results
Nov 7, 2022 04:05PM
Nov 3, 2022 05:55PM
Nov 3, 2022 04:01PM
Nov 3, 2022 04:01PM
Nov 3, 2022 04:01PM
Oct 17, 2022 12:33PM
Oct 3, 2022 05:49AM Apellis Pharmaceuticals (APLS) Reports Strong 24-Month Phase 3 Post Hoc Results of Pegcetacoplan
Sep 30, 2022 05:30PM
Sep 30, 2022 05:30PM
Sep 30, 2022 09:28AM
Sep 30, 2022 07:02AM
Sep 30, 2022 07:00AM
Sep 30, 2022 07:00AM
Aug 24, 2022 08:01AM Apellis Pharmaceuticals (APLS) Reports Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies
Aug 24, 2022 08:00AM
Aug 24, 2022 08:00AM
Aug 9, 2022 04:04AM
Aug 9, 2022 04:01AM
Aug 9, 2022 04:00AM
Aug 9, 2022 03:59AM
Aug 8, 2022 04:05PM Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results
Aug 8, 2022 04:05PM

15,414 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All